Introduction
============

Type 2 diabetes mellitus (T2DM) is a progressive and potentially debilitating chronic disease which can lead to kidney disease, retinopathy, neuropathy, and leg or foot ulcers in addition to increase risk for cardiovascular disease. T2DM is highly prevalent in the USA with recent estimates of 9.3% of the population having the condition[@b1-ijgm-10-177] and it is associated with a substantial economic and humanistic burden on society.[@b2-ijgm-10-177] To prevent the progression of T2DM and related complications, the most recent consensus guidelines of the American Diabetes Association (ADA) indicate that a concentration of glycosylated hemoglobin (HbA1c) ≥7.0% should serve as a trigger to initiate or escalate therapy.[@b3-ijgm-10-177] Notably, efforts to include treatment goals other than HbA1c targets such as quality of care, health status of the patient, and costs have been emphasized by guidance to improve patient-centered care.[@b3-ijgm-10-177]

Treatment escalation typically entails initiating therapy with oral monotherapy to adding more oral agents until a switch is made to insulin.[@b3-ijgm-10-177] In particular, the American Association of Clinical Endocrinologists (AACE) recommends the following suggested usage hierarchy for first-line monotherapy treatments when patients have HbA1c \<7.5%: metformin, glucagon-like peptide-1 (GLP-1) receptor agonist, sodium-glucose cotransporter (SGLT2) inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitor, or alpha-glucosidase inhibitor.[@b4-ijgm-10-177] Another oral treatment may be introduced in combination with a first-line oral agent if the HbA1c target is not reached within 3 months of monotherapy. According to AACE recommendations, caution should be taken with the addition of sulfonylurea/glinide (SU/GLN) or thiazolidinedione (TZD), with insulin in the combination treatment, due to the side effect profiles of SU/GLN and TZD, although ADA recommendations do not state this explicitly.[@b3-ijgm-10-177],[@b4-ijgm-10-177] In the case of a patient starting treatment with HbA1c ≥7.5%, dual oral therapy is indicated as first-line treatment. If the treatment goals are not met after 3 months of dual therapy, another agent may be added, including insulin. If patients start treatment with \>9.0% HbA1c, practitioners may use their discretion to start patients on dual or triple therapy and are advised to include insulin if there are diabetes-related symptoms present.[@b4-ijgm-10-177]

Evidence suggests that oral agents' effects on body weight, risk of hypoglycemia, gastrointestinal side effects, systolic blood pressure, and heart rate may substantially differ between classes of oral agents.[@b5-ijgm-10-177] Metformin, DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors have been found to reduce or maintain body weight, whereas SUs, TZDs, and insulin increase weight. SGLT2 inhibitors and GLP-1 agonists, in addition to metformin, have been found to reduce systolic blood pressure. There is a higher risk of cardiovascular events with SUs compared with metformin alone, and hypoglycemic events compared with most other treatments. Gastrointestinal side effects are more likely to occur with metformin than other agents, except GLP-1 agonists. SGLT2 inhibitors are associated with genital mycotic infections (GMIs).[@b5-ijgm-10-177]

Canagliflozin, the first SGLT2 inhibitor to be approved for the treatment of T2DM in the USA in March 2013, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.[@b6-ijgm-10-177] By inhibiting SGLT2, canagliflozin leads to the inhibition of glucose reabsorption and increased urinary glucose excretion, thereby reducing blood glucose, body weight, and blood pressure.[@b7-ijgm-10-177] Canagliflozin 300 mg also transiently blocks SGLT1 in the intestine, which reduces glucose absorption.[@b8-ijgm-10-177] In Phase III clinical trials, canagliflozin has been shown to improve HbA1c, body weight, and blood pressure, and to be generally well tolerated in patients with T2DM.[@b7-ijgm-10-177],[@b9-ijgm-10-177],[@b10-ijgm-10-177] Real-world studies have demonstrated similar improvements in HbA1c, body weight, and blood pressure among patients with T2DM using canagliflozin.[@b11-ijgm-10-177]--[@b14-ijgm-10-177] Moreover, canagliflozin's unique mechanism has been suggested to be associated with weight loss and a low risk of hypoglycemia adding to its potential of benefiting health status and reducing costs.[@b15-ijgm-10-177]

The current study seeks to understand how health care providers approached treatment with canagliflozin, assess perceptions of patient treatment experience with canagliflozin, and understand health care provider interactions with patients when discussing and initiating canagliflozin treatment.

Materials and methods
=====================

Sample and procedure
--------------------

US health care providers primary care physicians (PCPs; n=101), endocrinologists (n=101), and nurse practitioners/physician assistants (NP/PAs; n=100) were recruited into the survey. The sample for the study came from an online health care provider panel (Lightspeed All Global, part of Kantar Health), an actively managed double opt-in online panel where member registration and participation are maintained in the strictest confidence and are used purely for research purposes only. For this study, provider participants were targeted by specialty or type based on member registration profile. The physicians recruited for this study closely matched the demographics of the American Medical Association statistics with respect to age, gender, and region. Health care providers were invited to participate in this survey through an email invitation which contained the online survey link for self-administration from Lightspeed All Global or its panel partners. By clicking on the survey link, members were shown an informed consent form informing that participation is voluntary and responses will remain confidential detailing the research goals of the study. If agreed to, members will advance to the survey for completion. A convenience sample was used for health care provider recruitment; as such, no powering analysis was conducted. However, quotas were implemented to ensure close to equal representation of each provider type. Each eligible health care provider reported on their experiences with canagliflozin in a 15-minute Internet-based survey. This research study was submitted to the Pearl Institutional Review Board (Indianapolis, IN, USA) for review and was granted exemption status as this study involved survey/interview procedures only, with no participant identifiers collected and no survey content that would have put the participants at risk should it be disclosed.

Inclusion criteria
------------------

To participate in the study, health care providers must have consented to participate in the study, should be board certified or be board eligible (if an endocrinologist or PCP), have at least 1 year of experience in practice, be a part of the decision-making process for prescribing (if NP/PA) or have written canagliflozin and/or canagliflozin--metformin prescriptions to patients with T2DM (if an endocrinologist or PCP), managing or treating at least 40 patients with T2DM, and managing or treating patients with TD2M who are receiving an SGLT2 inhibitor (specifically having managed at least 6 patients on canagliflozin and/or canagliflozin--metformin for at least 3 months).

Measures
--------

The main grouping variable for this study was health care provider type, which had 3 groups: endocrinologists, PCPs, and NP/PAs. Health care providers reported on their primary specialty, sub-specialty, years in practice, gender, age, region of primary practice, practice specialty, and primary practice setting.

Health care providers were then asked what their perceptions of canagliflozin were when compared with other medication classes. Comparisons between canagliflozin and other medication classes for the treatment of T2DM (e.g., DPP-4s and SUs) were assessed on clinical characteristics, costs, and patient satisfaction. Confidence in canagliflozin's effect on various outcomes by line of therapy was also assessed. Health care providers reported on their current use of canagliflozin. Health care providers reported the proportion of patients who they prescribed SGLT2 inhibitors alone or in fixed-dose combination (FDC) with metformin or SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin, canagliflozin-metformin, dapagliflozin and metformin, empagliflozin and metformin for first through fourth lines). The health care provider's opinion on which characteristics identify a good patient candidate for canagliflozin, who makes the decision regarding treatments, and which attributes of canagliflozin are discussed, were also assessed.

Finally, providers reported on outcomes of patients on canagliflozin. Provider experience with canagliflozin on patient outcomes was assessed. In particular, the following were assessed: control of HbA1c, control of blood pressure, weight loss, quality of life (QoL), emotional response to diabetes management, adherence to treatment, behavioral changes, and outlook on diabetes management.

Analyses
--------

All analyses were carried out using SPSS version 20. All variables of interest were examined across provider type. Means and SDs were reported for continuous variables, and frequencies and percentages are reported for categorical variables. For categorical variables, chi-square tests were used to determine significant differences, whereas ANOVA was used for continuous variables when comparing provider types. An a priori null hypothesis threshold was set at *p*\<0.05.

Results
=======

Health care provider characteristics
------------------------------------

A nationwide sample of providers was recruited into the survey. Of the total 302 completed surveys, 101 were endocrinologists, 101 were PCPs (of those 52.5% were family medicine and 47.5% were internal medicine), and 100 were NP/PAs (of those 44% were NPs and 56% were PAs). NP/PAs reported specializing in the following: diabetes (45.0%), endocrinology (37.0%), family/general health/primary care (64.0%), and/or other (2.0%) ([Table 1](#t1-ijgm-10-177){ref-type="table"}). Refer [Table S1](#SD1-ijgm-10-177){ref-type="supplementary-material"} for practice patient characteristics.

Perceptions of canagliflozin
----------------------------

Health care providers reported higher favorability ratings of canagliflozin than DPP-4s on blood pressure and body weight and higher favorability ratings of canagliflozin than SUs on its effect on HbA1c, blood pressure, body weight, risk of hypoglycemia, overall treatment safety, and patient satisfaction. There were no significant differences between favorability ratings among endocrinologists, PCPs, and NP/PAs regarding the effect of canagliflozin versus DPP-4s on HbA1c or canagliflozin versus SUs on HbA1c. Favorability ratings regarding the effect of canagliflozin versus DPP-4s on blood pressure, and canagliflozin versus SUs on blood pressure, were found to significantly differ among endocrinologists, PCPs, and NP/PAs (*p*=0.029 and *p*=0.001, respectively), with endocrinologists having the most favorable view of canagliflozin. Although statistically different for canagliflozin versus SUs, favorability ratings were marginally different among endocrinologists, PCPs, and NP/PAs for effects on bodyweight for canagliflozin versus DPP-4s, with endocrinologists favoring canagliflozin (*p*=0.065). Favorability ratings on out-of-pocket costs for patients, risk of hypoglycemia, and patient satisfaction were not found to significantly differ among endocrinologists, PCPs, or NP/PAs ([Table 2](#t2-ijgm-10-177){ref-type="table"}).

Confidence by line of therapy
-----------------------------

More than 40% of endocrinologists and PCPs reported being very/extremely confident in canagliflozin as a first-line therapy, whereas \~20% reported being moderately confident and \~20% reported being slightly confident. The majority of NP/PAs reported being slightly/moderately confident. Confidence ratings on canagliflozin as second-, third-, or fourth-line therapy did not significantly differ among provider types. Health care providers reported being very/extremely satisfied with canagliflozin for the second-line (55%--59%), third-line (60%--74%), and fourth-line (59%--72%) therapy ([Table 3](#t3-ijgm-10-177){ref-type="table"}).

Current use of canagliflozin
----------------------------

The proportion of patients who were prescribed SGLT2 inhibitors alone or in FDC with metformin was higher from first-to third-line therapy, with a slight decrease to fourth-line therapy. The proportion of patients who were prescribed SGLT2 inhibitors alone or in FDC with metformin who were prescribed canagliflozin was similar across first-line through fourth-line therapy, and did not statistically differ by provider type. The proportion of patients prescribed SGLT2 inhibitors alone or in FDC with metformin did not significantly differ among provider types for first-through fourth-line therapy ([Table 4](#t4-ijgm-10-177){ref-type="table"}).

Canagliflozin prescribing
-------------------------

Health care providers were also asked to choose the top 3 characteristics from a list of 14 items (see full list in [Table 5](#t5-ijgm-10-177){ref-type="table"}) that identify a patient as a good candidate for canagliflozin. Endocrinologists, PCPs, and NP/PAs each most often chose "overweight or have weight concerns", "insurance coverage/affordability for long-term use", "good kidney function", "do not want an injectable/trying to delay injectables as long as possible", and "overall treatment safety", with no significant differences across provider types. Overall, 72%--85% of providers said that they made the final treatment decision often/always instead of their patients. This was found to differ among provider types with endocrinologists and PCPs reporting "often/always" making the final treatment decision for the patient (85.1%), whereas fewer NP/PAs reported the same way (71.7%) (*p*=0.016).

Various attributes of canagliflozin/canagliflozin--metformin treatment were discussed significantly less or more frequently depending on provider type. These included: copay cards (*p*=0.018), dosing and administration (*p*=0.012), urge/need for frequent urination (*p*=0.015), impact on weight (*p*=0.007), urinary tract infections (UTIs)/GMIs (*p*=0.017), risk of hypoglycemia (*p*=0.005), and overall treatment safety (*p*=0.039). The attributes most frequently discussed with patients were HbA1c reduction and potential for weight loss ([Table 5](#t5-ijgm-10-177){ref-type="table"}).

Canagliflozin outcomes
----------------------

Health care providers reported similar outcomes for their T2DM patients who were prescribed canagliflozin or FDC of canagliflozin with metformin. The majority of providers reported "often/always" observing patients' lowering or controlling HbA1c, weight loss, improvement in overall QoL, behaving positively by adhering to treatment and/or follow-up visits, and having a hopeful outlook for managing T2DM ([Table 6](#t6-ijgm-10-177){ref-type="table"}).

Discussion
==========

The Institute for Healthcare Improvement has developed the Triple Aim framework to optimize health care system performance. The Triple Aim framework calls for simultaneous pursuit of improvement in the health outcomes of populations, improvement in patients' experience of care, and reduction of per capita health care costs.[@b16-ijgm-10-177] Due to the high prevalence and chronic nature of T2DM, its comorbidity with other chronic conditions, and its numerous health complications, consideration of specific needs of patients with T2DM are necessary to reach the Triple Aim. In this study, health care providers reported experiencing improvements in 2 pillars of the Triple Aim framework, health outcomes and patients' experience of care, among patients using canagliflozin in real-world clinical practice.

Health care providers have witnessed positive clinical outcomes among patients using canagliflozin, including HbA1c lowering, weight loss, and blood pressure reduction. Indeed, providers viewed canagliflozin as more favorable than DPP-4s for its effect on blood pressure and body weight and more favorable than SUs for its effect on HbA1c, blood pressure, body weight, risk of hypoglycemia, and patient satisfaction. These findings are consistent with recent controlled trials which have shown that canagliflozin significantly reduces HbA1c, body weight, and systolic blood pressure. In particular, head-to-head trials have shown canagliflozin to be more efficacious than sitagliptin and SUs in improving these outcomes.[@b7-ijgm-10-177],[@b10-ijgm-10-177],[@b17-ijgm-10-177]--[@b19-ijgm-10-177]

Real-world observational studies further corroborate these clinical studies, suggesting that canagliflozin is effective in reducing HbA1c and lowering body weight.[@b20-ijgm-10-177] Notably, Thayer et al found that patients treated with canagliflozin were substantially more likely to reach the \<7% HbA1c target than patients treated with DPP-4 inhibitors.[@b12-ijgm-10-177] Indeed, the current study found that the attributes providers most frequently discussed with patients (when discussing canagliflozin) were HbA1c reduction and weight loss.

Health care providers reported positive experiences among patients using canagliflozin including improvement in overall QoL and having a more positive outlook and confidence in the management of their T2DM. Health care providers also observed improvement in patient behavioral outcomes including adherence to treatment and/or follow-up visits and changes to diet and exercise with the use of canagliflozin, which may have additional beneficial effects on clinical outcomes. Supporting these results, Buysman et al found that within a cohort of patients using canagliflozin, 86% were adherent to treatment over a 7-month period.[@b14-ijgm-10-177] Notably, although the current study did not assess adherence directly, but with physician recall of past patient behavior, it found similar results. Moreover, in clinical trials, canagliflozin use has been found to increase weight-related QoL and patient satisfaction.[@b21-ijgm-10-177] The weight loss associated with canagliflozin may act as positive feedback and lead to improvements in self-management behaviors including diet and exercise, which, in turn, leads to further weight loss and improvement in other clinical outcomes.[@b21-ijgm-10-177]

Health care providers reported confidence in the use of canagliflozin as a treatment option for patients with T2DM, especially for use after metformin. Confidence was high, even in first-line treatment, although it was greater in the third and fourth line. This is consistent with AACE and ADA guidelines, which advise metformin to be used as first-line monotherapy unless contraindicated.[@b3-ijgm-10-177],[@b4-ijgm-10-177]

This study adds to the growing body of literature providing real-world canagliflozin management experiences from health care providers, consisting of physician specialists, nonspecialists, and NA/PAs. Overall, providers reported favorable glycemic control, hypoglycemic risk, and weight loss. Health care providers also reported confidence in prescribing, and an improved overall experience of their patients in the management of their diabetes, in their practice setting, using canagliflozin.

Limitations
===========

Although the study relied on self-reported evidence, selfreport is the only way to measure health care provider perceptions and personal experiences with treatment. The survey was cross-sectional; and therefore, not amenable to causal conclusions that may be drawn from an experimental and/or longitudinal survey. Representativeness was limited to providers identified through a panel, and further limited to respondents with access and motivation to participate in online studies. The provider's perception and experience with canagliflozin, compared with other SGLT2 inhibitors, regarding effectiveness and safety was not assessed in this current research study. Additional research is considered necessary to evaluate whether the physician-reported differences in health outcomes in the current study can be replicated by directly assessing patient outcomes in clinical practice.

Conclusion
==========

Despite its relatively short time on the market, health care providers have reported favorable experiences with canagliflozin and canagliflozin--metformin FDC therapy. Specifically, health care providers have witnessed improvements in multiple clinical outcomes, as well as improvements in patients' experiences and even patients' self-management behaviors, among patients using canagliflozin. These outcomes should be viewed in the context of the Triple Aim framework given provider perception of improvement in health status and quality of care, which could affect costs.

Supplementary materials
=======================

###### 

Patient characteristics by provider type

  Patient characteristics                                   Provider type   One-way ANOVA *p*-value                                           
  --------------------------------------------------------- --------------- ------------------------- ------------ ------- ---------- ------- --------------------------
  Age (% of patients, years)                                                                                                                  
    \<18                                                    2.46^a^         4.27                      2.98^a^      5.29    3.00^a^    4.38    0.644
   18--44                                                   21.83^a,b^      9.29                      20.03^a^     12.2    23.60^b^   11.03   0.069
   45--64                                                   35.62^a^        11.89                     35.93^a^     13.84   37.19^a^   12.28   0.652
   65--74                                                   25.01^a^        8.94                      26.30^a^     12.75   24.81^a^   13.3    0.625
   ≥75                                                      15.08^a^        8.13                      14.76^a^     11.04   11.40^b^   11.54   0.021
  Ethnicity (% of patients)                                                                                                                   
   White                                                    60.41^a^        21.32                     59.72^a^     26.83   46.80^b^   23.08   \<0.001
   Black or African American                                16.93^a^        11.81                     17.61^a^     14.82   24.17^b^   16.73   0.001
   Hispanic or Latino                                       12.89^a^        10.45                     13.75^a^     15.35   18.79^b^   15.81   0.006
   Asian                                                    7.01^a^         7.72                      6.96^a^      11.38   5.91^a^    5.93    0.597
   Other (mixed racial background, native American, etc.)   2.76^a,b^       5.3                       1.95^a^      4.69    4.33^b^    11.03   0.078
  Insurance (% of patients)                                                                                                                   
   Commercial                                               56.16^a^        18.43                     52.34^a^     19.13   43.61^b^   20.2    \<0.001
   Medicaid                                                 10.10^a^        10.38                     11.28^a^     11.15   19.17^b^   18.29   \<0.001
   Medicare                                                 29.92^a^        13.69                     29.76^a^     15.77   32.76^a^   14.18   0.262
   Uninsured                                                3.65^a^         4.4                       6.93^b^      8.96    6.78^b^    6.82    0.001
   Other                                                    1.36^a^         10.09                     0.11^a^      0.65    0.78^a^    6.57    0.445
  HbA1c level (% of patients)                                                                                                                 
   \<7.0                                                    34.80^a^        20.53                     41.33^b^     21.57   30.97^a^   19.45   0.002
   7.0--7.9                                                 28.06^a^        11.57                     29.82^a,b^   12.63   31.60^b^   12.71   0.127
   8.0--9.0                                                 22.15^a^        12.37                     18.04^b^     11      23.06^a^   11.24   0.005
   \>9.0                                                    14.99^a^        8.92                      10.81^b^     8.01    14.37^a^   9.11    0.001
                                                                                                                                              
                                                            **N**           **%**                     **N**        **%**   **N**      **%**   **Chi-square *p*-value**
                                                                                                                                              
  Patient's education level                                                                                                                   
   High School or less                                      35^a^           34.70                     37^a,b^      36.60   49^b^      49.00   0.083
   College or more                                          41^a^           40.60                     40^a^        39.60   24^b^      24.00   
   Do not know                                              25^a^           24.80                     24^a^        23.80   27^a^      27.00   

**Notes:** For pairwise comparisons, refer to superscripts (e.g., a, b, c) attached to column means. Column means in the same row that do not share the same superscripts (e.g., XX^a^ vs XX^b^) are significantly different at *p*\<0.05. If the values share the same superscripts (e.g., XX^a^ vs XX^a^ or XX^a,b^ vs XX^a^) then they are not significantly different at *p*\<0.05.

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants; ANOVA, analysis of variance; HbA1c, glycosylated hemoglobin.
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###### 

Characteristics of providers and practices

  Measures                                                                    Provider type   One-way ANOVA *p*-value                                               
  --------------------------------------------------------------------------- --------------- ------------------------- -------- ------ ------- ------ ----- ------ -----------------------------------------------------
  Provider gender                                                                                                                                                   
   Female                                                                     19^a^           18.8                      22^a^    21.8   74^b^   74.0   115   38.1   \<0.001
  Provider age (years)                                                                                                                                              
   \<45                                                                       36^a^           35.6                      22^b^    21.8   50^c^   50.0   108   35.8   \<0.001[\*](#tfn1-ijgm-10-177){ref-type="table-fn"}
   45--64                                                                     54^a^           53.5                      71^b^    70.3   48^a^   48.0   173   57.3   
   \>65                                                                       7^a^            6.9                       5^a,b^   5.0    1^b^    1.0    13    4.3    
   Decline to answer                                                          4^a^            4.0                       3^a^     3.0    1^a^    1.0    8     2.6    
  Provider private practice setting                                                                                                                                 
   Private solo practice                                                      22^a,b^         21.8                      30^a^    29.7   15^b^   15.0   67    22.2   \<0.001[\*](#tfn1-ijgm-10-177){ref-type="table-fn"}
   Private group practice                                                     57^a^           56.4                      61^a^    60.4   55^a^   55.0   173   57.3   
   Health system                                                              16^a^           15.8                      8^a^     7.9    13^a^   13.0   37    12.3   
   Other (e.g., stand-alone hospital, community center, or diabetes center)   6^a^            5.9                       2^a^     2.0    17^b^   17.0   25    8.3    

**Notes:**

Test of independence conducted using Fisher's exact test when counts are \<5. For pairwise comparisons, refer to superscripts (e.g., a, b, c) attached to column percentages. Column percentages in the same row that do not share the same superscripts (e.g., XX^a^ vs XX^b^) are significantly different at *p*\<0.05. If the values share the same superscripts (e.g., XX^a^ vs XX^a^ or XX^a,b^ vs XX^a^) then they are not significantly different at *p*\<0.05.

**Abbreviations:** ANOVA, analysis of variance; PCP, primary care physician; NP/PA, nurse practitioners/physician assistants.

###### 

Canagliflozin/canagliflozin-metformin compared to DPP-4 inhibitor attributes for the treatment of T2DM by provider type

  Measures                             Canagliflozin/canagliflozin-metformin compared to DPP-4s   Canagliflozin/canagliflozin-metformin compared to SUs                                                                                           
  ------------------------------------ ---------------------------------------------------------- ------------------------------------------------------- --------- ------ --------- ------ ------- ------- ------ -------- ------ ------- ------ ---------------------------------------------------
  **Effect on HbA1c**                                                                                                                                                                                                                             
  More favorable                       45^a^                                                      44.6                                                    26^b^     25.7   38^a,b^   38.0   0.089   41      40.6   47       46.5   49      49.0   0.106[\*](#tfn3-ijgm-10-177){ref-type="table-fn"}
  Equally favorable                    39^a^                                                      38.6                                                    46^a^     45.5   45^a^     45.0           34      33.7   24       23.8   36      36.0   
  Less favorable                       12^a^                                                      11.9                                                    23^b^     22.8   12^a^     12.0           23      22.8   24       23.8   11      11.0   
  Do not know                          5^a^                                                       5.0                                                     6^a^      5.9    5^a^      5.0            3       3.0    6        5.9    4       4.0    
  **Effect on blood pressure**                                                                                                                                                                                                                    
  More favorable                       64^a^                                                      63.4                                                    40^b^     39.6   49^b^     49.0   0.029   82^a^   81.2   64^b^    63.4   56^b^   56.0   0.001[\*](#tfn3-ijgm-10-177){ref-type="table-fn"}
  Equally favorable                    26^a^                                                      25.7                                                    37^a^     36.6   31^a^     31.0           11^a^   10.9   28^b^    27.7   24^b^   24.0   
  Less favorable                       6^a^                                                       5.9                                                     16^b^     15.8   10^a,b^   10.0           6^a^    5.9    5^a^     5.0    9^a^    9.0    
  Do not know                          5^a^                                                       5.0                                                     8^a^      7.9    10^a^     10.0           2^a^    2.0    4^a,b^   4.0    11^b^   11.0   
  **Effect on body weight**                                                                                                                                                                                                                       
  More favorable                       62^a^                                                      61.4                                                    44^b^     43.6   52^a,b^   52.0   0.065   79      78.2   70       69.3   72      72.0   0.653[\*](#tfn3-ijgm-10-177){ref-type="table-fn"}
  Equally favorable                    22^a^                                                      21.8                                                    35^b^     34.7   34^a,b^   34.0           11      10.9   18       17.8   17      17.0   
  Less favorable                       10^a,b^                                                    9.9                                                     15^a^     14.9   5^b^      5.0            8       7.9    11       10.9   7       7.0    
  Do not know                          7^a^                                                       6.9                                                     7^a^      6.9    9^a^      9.0            3       3.0    2        2.0    4       4.0    
  **Out-of-pocket cost for patient**                                                                                                                                                                                                              
  More favorable                       20                                                         19.8                                                    18        17.8   30        30.0   0.339   28      27.7   16       15.8   19      19.0   0.164[\*](#tfn3-ijgm-10-177){ref-type="table-fn"}
  Equally favorable                    39                                                         38.6                                                    40        39.6   39        39.0           11      10.9   21       20.8   19      19.0   
  Less favorable                       29                                                         28.7                                                    26        25.7   19        19.0           59      58.4   57       56.4   55      55.0   
  Do not know                          13                                                         12.9                                                    17        16.8   12        12.0           3       3.0    7        6.9    7       7.0    
  **Risk of hypoglycemia**                                                                                                                                                                                                                        
  More favorable                       12^a^                                                      11.9                                                    18^a,b^   17.8   23^b^     23.0   0.064   76      75.2   63       62.4   63      63.0   0.231[\*](#tfn3-ijgm-10-177){ref-type="table-fn"}
  Equally favorable                    70^a^                                                      69.3                                                    56^b^     55.4   46^b^     46.0           12      11.9   19       18.8   24      24.0   
  Less favorable                       14^a^                                                      13.9                                                    18^a^     17.8   23^a^     23.0           8       7.9    14       13.9   10      10.0   
  Do not know                          5^a^                                                       5.0                                                     9^a^      8.9    8^a^      8.0            5       5.0    5        5.0    3       3.0    
  **Patient satisfaction**                                                                                                                                                                                                                        
  More favorable                       24                                                         23.8                                                    17        16.8   23        23.0   0.550   49      48.5   43       42.6   49      49.0   0.315
  Equally favorable                    44                                                         43.6                                                    52        51.5   53        53.0           31      30.7   40       39.6   40      40.0   
  Less favorable                       25                                                         24.8                                                    21        20.8   16        16.0           11      10.9   13       12.9   6       6.0    
  Do not know                          8                                                          7.9                                                     11        10.9   8         8.0            10      9.9    5        5.0    5       5.0    

**Notes:**

Test of independence conducted using Fisher's exact test when counts are \<5. For pairwise comparisons, refer to superscripts (e.g., a, b, c) attached to column percentages. Column percentages in the same row that do not share the same superscripts (e.g., XX^a^ vs XX^b^) are significantly different at *p*\<0.05. If the values share the same superscripts (e.g., XX^a^ vs XX^a^ or XX^a,b^ vs XX^a^) then they are not significantly different at *p*\<0.05.

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants; T2DM, type 2 diabetes mellitus; DPP4, dipeptidyl peptidase-4; SU, sulfonylureas; HbA1c, glycosylated hemoglobin.

###### 

Confidence in canagliflozin/canagliflozin-metformin for each line of therapy

  Line of Therapy        Provider type   Chi-square *p*-value or Fisher's exact test[\*](#tfn5-ijgm-10-177){ref-type="table-fn"}                                                
  ---------------------- --------------- ----------------------------------------------------------------------------------------- --------- ------ ------- ------ ----- ------ ---------------------------------------------------
  **First line**                                                                                                                                                                
  Not at all confident   24^a^           23.8                                                                                      20^a,b^   19.8   13^b^   13.0   57    18.9   0.003
  Slightly confident     18^a^           17.8                                                                                      19^a^     18.8   33^b^   33.0   70    23.2   
  Moderately confident   15^a^           14.9                                                                                      19^a,b^   18.8   28^b^   28.0   62    20.5   
  Very confident         34^a^           33.7                                                                                      25^a,b^   24.8   17^b^   17.0   76    25.2   
  Extremely confident    10^a^           9.9                                                                                       18^a^     17.8   9^a^    9.0    37    12.3   
  **Second line**                                                                                                                                                               
  Not at all confident   3^a^            3.0                                                                                       4^a^      4.0    4^a^    4.0    11    3.6    0.772[\*](#tfn5-ijgm-10-177){ref-type="table-fn"}
  Slightly confident     14^a^           13.9                                                                                      11^a^     10.9   9^a^    9.0    34    11.3   
  Moderately confident   24^a^           23.8                                                                                      30^a^     29.7   31^a^   31.0   85    28.1   
  Very confident         42^a^           41.6                                                                                      32^a^     31.7   38^a^   38.0   112   37.1   
  Extremely confident    18^a^           17.8                                                                                      24^a^     23.8   18^a^   18.0   60    19.9   
  **Third line**                                                                                                                                                                
  Not at all confident   1^a^            1.0                                                                                       1^a^      1.0    0       0.0    2     0.7    0.149[\*](#tfn5-ijgm-10-177){ref-type="table-fn"}
  Slightly confident     4^a^            4.0                                                                                       8^a^      7.9    4^a^    4.0    16    5.3    
  Moderately confident   35^a^           34.7                                                                                      18^b^     17.8   22^b^   22.0   75    24.8   
  Very confident         42^a^           41.6                                                                                      47^a^     46.5   50^a^   50.0   139   46.0   
  Extremely confident    19^a^           18.8                                                                                      27^a^     26.7   24^a^   24.0   70    23.2   
  **Fourth line**                                                                                                                                                               
  Not at all confident   3^a^            3.0                                                                                       3^a^      3.0    1^a^    1.0    7     2.3    0.409[\*](#tfn5-ijgm-10-177){ref-type="table-fn"}
  Slightly confident     9^a^            8.9                                                                                       5^a^      5.0    10^a^   10.0   24    7.9    
  Moderately confident   29^a^           28.7                                                                                      22^a,b^   21.8   17^b^   17.0   68    22.5   
  Very confident         40^a^           39.6                                                                                      44^a^     43.6   43^a^   43.0   127   42.1   
  Extremely confident    20^a^           19.8                                                                                      27^a^     26.7   29^a^   29.0   76    25.2   

**Notes:**

Test of independence conducted using Fisher's exact test when counts are \<5. For pairwise comparisons, refer to superscripts (e.g., a, b, c) attached to column percentages. Column percentages in the same row that do not share the same superscripts (e.g., XX^a^ vs XX^b^) are significantly different at *p*\<0.05. If the values share the same superscripts (e.g., XX^a^ vs XX^a^ or XX^a,b^ vs XX^a^) then they are not significantly different at *p*\<0.05.

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants.

###### 

Prescribing by provider type for each line of therapy

  --------------------------------------------------------------------------------------------------------------
  Line of therapy                                   Provider type                                       
  ------------------------------------------------- --------------- -------- -------- -------- -------- --------
  **First line**                                                                                        

  SGLT2 inhibitors alone or in FDC with metformin   5.04\           7.61\    5.8\     7.21\    5.6\     7.96\
                                                    41.47           23.1     41.72    22.2     46.03    21.1

  **Second line**                                                                                       

  SGLT2 inhibitors alone or in FDC with metformin   12.61\          10.89\   11.48\   8.19\    12.01\   10.52\
                                                    43.11           23.18    45.89    21.82    49.39    24.86

  **Third line**                                                                                        

  SGLT2 inhibitors alone or in FDC with metformin   15.68\          13.96\   13.76\   11.22\   12.73\   10.32\
                                                    45.34           24.14    44.82    22.38    51.74    24.52

  **Fourth line**                                                                                       

  SGLT2 inhibitors alone or in FDC with metformin   12.03\          10.66\   10.63\   10.95\   11.25\   12.17\
                                                    42.6            25.65    42.33    20.25    46.45    23.63
  --------------------------------------------------------------------------------------------------------------

**Notes:** Sample sizes for those who prescribed SLGT2 inhibitors for first line: endocrinologist (n=62), PCP (n=65), NP/PA (n=59); line 2: endocrinologist (n=88), PCP (n=87), NP/PA (n=85); line 3: endocrinologist (n=90), PCP (n=87), NP/PA (n=86); line 4: endocrinologist (n=83), PCP (n=73), NP/PA (n=69). There were no statistically significant differences across provider type.

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants; FDC, fixed-dose combination.

###### 

Canagliflozin/canagliflozin-metformin prescribing

                                                                                                                  Provider type                                                               Chi-square *p*-value or Fisher's exact test[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}                         
  --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------- ----------- ---------------------------------------------------
  **Characteristics ranked as top 3 that make a patient a good candidate**                                                                                                                                                                                                                                    
                                                                                                                  Good kidney function                                                        36.6                                                                                      29.7      42.0        0.191
                                                                                                                  Good liver function                                                         3.0                                                                                       4.0       9.0         0.120[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}
                                                                                                                  No history of UTI                                                           19.8                                                                                      9.9       13.0        0.120
                                                                                                                  No history of GMI                                                           10.9                                                                                      7.9       10.0        0.763
                                                                                                                  Overweight or have weight concerns                                          47.5                                                                                      48.5      47.0        0.976
                                                                                                                  Blood pressure                                                              13.9                                                                                      12.9      10.0        0.687
                                                                                                                  History of hypoglycemia                                                     19.8                                                                                      24.8      16.0        0.301
                                                                                                                  Been on other T2DM treatments for a long time                               18.8                                                                                      16.8      13.0        0.525
                                                                                                                  Do not want an injectable/trying to delay injectables as long as possible   36.6                                                                                      35.6      38.0        0.941
                                                                                                                  Insurance coverage/affordability for long-term use                          38.6                                                                                      44.6      42.0        0.692
                                                                                                                  Willing to take a medication that is "new" to market                        7.9                                                                                       11.9      10.0        0.642
                                                                                                                  Willing to accept or put up with frequent urination                         12.9^a^                                                                                   22.8^a^   13.0^a^     0.091
                                                                                                                  Overall treatment safety                                                    31.7                                                                                      29.7      37.0        0.523
                                                                                                                  Other                                                                       2.0                                                                                       1.0       0.0         1.000[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}
  The treatment discussion and treatment decision maker                                                                                                                                                                                                                                                       
  Provider makes the final treatment decision                                                                     Never                                                                       2^a^                                                                                      2^a^      0.0         0.010[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}
                                                                                                                  Rarely/sometimes                                                            12.9^a^                                                                                   12.9^a^   28.3^b^     
                                                                                                                  Often/always                                                                85.1 ^a^                                                                                  85.1^a^   71.7^b^     
  Provider discusses treatment and then makes recommendation                                                      Never                                                                       1.0                                                                                       2.0       1.0         0.897[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}
                                                                                                                  Rarely/sometimes                                                            9.9                                                                                       6.9       7.1         
                                                                                                                  Often/always                                                                89.1                                                                                      91.1      91.9        
  Provider discusses treatment and patient makes decision                                                         Never                                                                       3.0                                                                                       2.0       1.0         0.950[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}
                                                                                                                  Rarely/sometimes                                                            50.5                                                                                      49.5      51.5        
                                                                                                                  Often/always                                                                46.5                                                                                      48.5      47.5        
  Attributes of canagliflozin/canagliflozin-metformin typically discussed when discussing as a treatment option                                                                                                                                                                                               
  Attributes typically discussed                                                                                  Mechanism of action                                                         67.7                                                                                      59.0      65.0        0.426
                                                                                                                  Copay cards offered by manufacturer                                         49.5^a,b^                                                                                 40^a^     60^b^       0.018
                                                                                                                  Dosing and administration                                                   59.6^a^                                                                                   53^a^     73^b^       0.012
                                                                                                                  Urge/need for frequent urination                                            54.5^a^                                                                                   37^b^     55^a^       0.015
                                                                                                                  Out-of-pocket cost                                                          41.4                                                                                      49.0      56.0        0.120
                                                                                                                  Insurance coverage                                                          47.5                                                                                      54.0      59.0        0.263
                                                                                                                  Concomitant medication use                                                  29.3                                                                                      26.0      39.0        0.120
                                                                                                                  HbA1c reduction                                                             75.8                                                                                      81.0      79.0        0.661
                                                                                                                  Impact on weight                                                            81.8^a^                                                                                   63^b^     77^a^       0.007
                                                                                                                  Lowering of systolic blood pressure                                         58.6^a^                                                                                   44^b^     44^b^       0.060
                                                                                                                  Potential rise in low-density lipoprotein (LDL) cholesterol                 26.3                                                                                      16.0      24.0        0.185
                                                                                                                  UTI and/or GMI                                                              77.8^a^                                                                                   59.0^b^   67.0^a,b^   0.017
                                                                                                                  Risk of hypoglycemia                                                        54.5^a^                                                                                   36.0^b^   57.0^a^     0.005
                                                                                                                  Overall treatment safety                                                    47.5^a,b^                                                                                 38.0^a^   56.0^b^     0.039
                                                                                                                  Other                                                                       3.0                                                                                       1.0 3.0               0.641[\*](#tfn9-ijgm-10-177){ref-type="table-fn"}

**Note:**

Test of independence conducted using Fisher's exact test when counts are \<5. For pairwise comparisons, refer to superscripts (e.g., a, b, c) attached to column percentages. Column percentages in the same row that do not share the same superscripts (e.g., XX^a^ vs XX^b^) are significantly different at *p*\<0.05. If the values share the same superscripts (e.g., XX^a^ vs XX^a^ or XX^a,b^ vs XX^a^) then they are not significantly different at *p*\<0.05. Only includes respondents who indicated that canagliflozin/canagliflozin-metformin was included in treatment discussion: endocrinologist (n=99), PCP (n=100), NP/PA (n=100).

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants; UTI, urinary tract infection; GMI, genital mycotic infection; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin.

###### 

Positive changes observed by provider type (categorical) when managing patients with T2DM on canagliflozin/canagliflozin-metformin

  Outcomes                                                               Provider type          
  ---------------------------------------------------------------------- --------------- ------ ------
  Lowering/controlling HbA1c                                                                    
   Never                                                                 0.0             0.0    1.0
   Rarely                                                                1.0             0.0    0.0
   Sometimes                                                             14.9            17.8   11.0
   Often/always                                                          84.2            82.2   88.0
  Lowering/controlling blood pressure                                                           
   Rarely                                                                7.9             6.9    6.0
   Sometimes                                                             43.6            45.5   43.0
   Often/always                                                          48.5            47.5   51.0
  Weight loss                                                                                   
   Never                                                                 0.0             0.0    1.0
   Rarely                                                                4.0             6.9    3.0
   Sometimes                                                             27.7            33.7   43.0
   Often/always                                                          68.3            59.4   53.0
  Improvement in overall quality of life                                                        
   Never                                                                 1.0             0.0    0.0
   Rarely                                                                6.9             7.9    5.0
   Sometimes                                                             39.6            41.6   45.0
   Often/always                                                          52.5            50.5   50.0
  Feeling emotionally better that their T2DM is being managed well                              
   Never                                                                 0.0             1.0    0.0
   Rarely                                                                5.0             6.9    6.0
   Sometimes                                                             46.5            34.7   33.0
   Often/always                                                          48.5            57.4   61.0
  Behaving positively by adhering to treatment and/or follow-up visits                          
   Never                                                                 1.0             1.0    0.0
   Rarely                                                                5.9             5.0    4.0
   Sometimes                                                             38.6            37.6   33.0
   Often/always                                                          54.5            56.4   63.0
  Behaving positively by making changes to diet and exercise                                    
   Never                                                                 1.0             0.0    0.0
   Rarely                                                                9.9             9.9    9.0
   Sometimes                                                             39.6            41.6   43.0
   Often/always                                                          49.5            48.5   48.0
  Having a hopeful outlook for managing T2DM                                                    
   Never                                                                 1.0             0.0    0.0
   Rarely                                                                3.0             2.0    6.0
   Sometimes                                                             41.6            40.6   37.0
   Often/always                                                          54.5            57.4   57.0

**Note:** There were no statistically significant differences across provider type.

**Abbreviations:** PCP, primary care physician; NP/PA, nurse practitioners/physician assistants; T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin.
